公开(公告)号：US12097190B2

公开(公告)日：2024-09-24

申请号：US17739648

申请日：2022-05-09

Applicant: Alpha-1 Biologics, LLC

Inventor： Cynthia L. Bristow ,  Ronald H. Winston

IPC: A61K31/43 ,  A61K31/407 ,  A61K31/431 ,  A61K31/545 ,  A61K31/546 ,  A61K39/395 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00

CPC classification number: A61K31/43 ,  A61K31/407 ,  A61K31/431 ,  A61K31/545 ,  A61K31/546 ,  A61K39/39533 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00 ,  A61K31/407 ,  A61K2300/00 ,  A61K31/43 ,  A61K2300/00 ,  A61K31/431 ,  A61K2300/00 ,  A61K31/545 ,  A61K2300/00 ,  A61K31/546 ,  A61K2300/00 ,  A61K39/39533 ,  A61K2300/00

Abstract: A method for increasing the number of CD4+ T-lymphocytes in the serum of a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an amount of an L-isomer of β-lactam effective to increase the number of CD4+ T-lymphocytes in said patient's serum.

公开(公告)号：US20240226084A9

公开(公告)日：2024-07-11

申请号：US18400716

申请日：2023-12-29

Applicant: Techfields Pharma Co., Ltd.

Inventor： Chongxi Yu ,  Lina Xu

IPC: A61K31/4545 ,  A61K31/135 ,  A61K31/381 ,  A61K31/43 ,  A61K31/445 ,  A61K31/47 ,  A61K31/625 ,  A61K45/06 ,  A61K47/54

CPC classification number: A61K31/4545 ,  A61K31/135 ,  A61K31/381 ,  A61K31/43 ,  A61K31/445 ,  A61K31/47 ,  A61K31/625 ,  A61K45/06 ,  A61K47/54

Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

公开(公告)号：US20240197702A1

公开(公告)日：2024-06-20

申请号：US17909869

申请日：2021-03-10

Applicant: Board of Supervisors of Lousiana State University and Agricultural and Mechanical College

Inventor： Isiah Manuel WARNER ,  Jeffrey Andre HOBDEN ,  Kelsey Marie LOPEZ

IPC: A61K31/444 ,  A61K31/43 ,  A61P31/04

CPC classification number: A61K31/444 ,  A61K31/43 ,  A61P31/04

Abstract: Ion-pairs known as GUMBOS (group of uniform materials based on organic salts) from antiseptics (chlorhexidine and octenidine) and the beta-lactam antibiotic, ceftriaxone. The antimicrobial efficacy of these GUMBOS and unreacted stoichiometric equivalent mixtures were compared to ceftriaxone and azithromycin alone. On a molar basis, GUMBOS were equivalent to ceftriaxone and 10× more effective in killing N. gonorrhoeae than azithromycin. They were more than 100× more effective than either antibiotic in killing CRE. A strategy involving the electrostatic interaction between a common antiseptic and a discontinued antibiotic (octenidine and carbenicillin) was also evaluated as a treatment for gonorrhoea. Octenidine/carbenicillin is a novel group of uniform materials based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antiseptic and antibacterial ions, octenidine and carbenicillin, respectively.

公开(公告)号：US20240180839A1

公开(公告)日：2024-06-06

申请号：US18492284

申请日：2023-10-23

Applicant: PHARMAQUEST INTERNATIONAL CENTER, LLC

Inventor： Mohammad Amin MOHAMMAD

IPC: A61K9/20 ,  A61K9/16 ,  A61K9/28 ,  A61K9/50 ,  A61K31/00 ,  A61K31/424 ,  A61K31/43

CPC classification number: A61K9/2081 ,  A61K9/1682 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2866 ,  A61K9/5084 ,  A61K31/00 ,  A61K31/424 ,  A61K31/43

Abstract: The present invention relates to a modified release pharmaceutical formulation comprising one or more sustained release granules that may be prepared by over-mixing and hot melt granulation. The invention also relates to disintegrating monolithic modified release tablets comprising the sustained release granules as an internal phase and an immediate release formulation of a drug or drugs as an external phase. The drug release profile from either these granules or these tables may be adjusted by adjusting the percentages of the formulation's components. In one application, the disintegrating monolithic modified release tablets comprise amoxicillin and clavulanate and have a dissolution profile similar to brand and generic “Augmentin XR® Bilayered Extended Release Tablets (1000 mg/62.5 mg)”. The invention also relates to a method of preparing the foregoing sustained release granules.

公开(公告)号：US11998560B2

公开(公告)日：2024-06-04

申请号：US17266219

申请日：2019-11-22

Applicant: University of Manitoba

Inventor： Frank Schweizer ,  Temilolu Idowu ,  Derek Ammeter

IPC: A61K31/7036 ,  A61K31/407 ,  A61K31/427 ,  A61K31/43 ,  A61K31/545 ,  A61K47/54 ,  A61P31/04 ,  C07H15/26

CPC classification number: A61K31/7036 ,  A61K31/407 ,  A61K31/427 ,  A61K31/43 ,  A61K31/545 ,  A61K47/547 ,  A61P31/04 ,  C07H15/26

Abstract: Herein, we describe the development of non-β-lactam-based potentiator molecules that synergize with β-lactam antibiotics and β-lactam-β-lactamase inhibitor combinations against MDR/XDR P. aeruginosa phenotypes. The compound comprises a chemical structure or chemical formula of Formula (A) or a suitable salt form thereof, wherein “n” is a carbon tether having a length of between about 2-18 carbons.

公开(公告)号：US11944669B2

公开(公告)日：2024-04-02

申请号：US18163648

申请日：2023-02-02

Applicant: Theriva Biologics, Inc.

Inventor： Michael Kaleko ,  Sheila Connelly ,  Vincent John Wacher

IPC: A61K38/50 ,  A61K9/16 ,  A61K9/50 ,  A61K31/4164 ,  A61K31/424 ,  A61K31/43 ,  A61K31/7056 ,  A61K35/74 ,  A61K35/741 ,  A61K38/14 ,  A61K45/06

CPC classification number: A61K38/50 ,  A61K9/1652 ,  A61K9/5078 ,  A61K31/4164 ,  A61K31/424 ,  A61K31/43 ,  A61K31/7056 ,  A61K35/74 ,  A61K35/741 ,  A61K38/14 ,  A61K45/06 ,  A61K9/5026 ,  A61K9/5047 ,  C12Y305/02006 ,  A61K38/14 ,  A61K2300/00 ,  A61K38/50 ,  A61K2300/00 ,  A61K31/7056 ,  A61K2300/00 ,  A61K31/43 ,  A61K2300/00 ,  A61K31/424 ,  A61K2300/00

Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

公开(公告)号：US20240082229A1

公开(公告)日：2024-03-14

申请号：US18363006

申请日：2023-08-01

Applicant: TENNOR THERAPEUTICS (SUZHOU) LIMITED

Inventor： Zhenkun MA ,  Guozhu GENG ,  Jing CHEN ,  Yu LIU ,  Xiangyi XU ,  Changlin AI ,  Junlei ZHANG ,  Ting SONG ,  Shuangshuang ZHAO

IPC: A61K31/439 ,  A61K9/28 ,  A61K9/48 ,  A61K31/43 ,  A61K31/4439 ,  A61P31/04

CPC classification number: A61K31/439 ,  A61K9/28 ,  A61K9/48 ,  A61K31/43 ,  A61K31/4439 ,  A61P31/04

Abstract: The present disclosure provides methods, drug combinations and kits for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in a patient in need thereof.

公开(公告)号：US20240050541A1

公开(公告)日：2024-02-15

申请号：US18267408

申请日：2021-12-21

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： Stanley C. Jordan ,  Noriko Ammerman ,  Ashley Vo ,  Irene Kim ,  Sanjeev Kumar

IPC: A61K38/57 ,  A61K31/5377 ,  A61K31/522 ,  A61K31/43 ,  A61K31/573 ,  A61P37/06

CPC classification number: A61K38/57 ,  A61K31/5377 ,  A61K31/522 ,  A61K31/43 ,  A61K31/573 ,  A61P37/06

Abstract: The present invention describes method for reducing Delayed Graft Function (DGF) and Ischemia/Reperfusion Injury (IRI) by intra-renal infusion of a C1 esterase inhibitor.

公开(公告)号：US20240050489A1

公开(公告)日：2024-02-15

申请号：US18485872

申请日：2023-10-12

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Matthew J. HAMILTON ,  Alexander KHORUTS ,  Michael J. SADOWSKY ,  Christopher M. STALEY

IPC: A61K35/74 ,  A01N1/02 ,  A61K9/00 ,  A61P31/04 ,  A61K9/19 ,  A61K31/43 ,  A61K9/16 ,  A61K9/20

CPC classification number: A61K35/74 ,  A01N1/02 ,  A61K9/0053 ,  A61P31/04 ,  A61K9/19 ,  A61K31/43 ,  A61K9/1682 ,  A61K9/2095 ,  A61K9/1623

Abstract: The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.

公开(公告)号：US11857545B2

公开(公告)日：2024-01-02

申请号：US14542486

申请日：2014-11-14

Applicant: TECHFIELDS PHARMA CO., LTD.

Inventor： Chongxi Yu ,  Lina Xu

IPC: A61K31/47 ,  A61K47/54 ,  A61K31/4545 ,  A61K31/135 ,  A61K31/43 ,  A61K31/445 ,  A61K31/381 ,  A61K31/625 ,  A61K45/06

CPC classification number: A61K31/4545 ,  A61K31/135 ,  A61K31/381 ,  A61K31/43 ,  A61K31/445 ,  A61K31/47 ,  A61K31/625 ,  A61K45/06 ,  A61K47/54

Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.